The objective response rate with approved anti-PD-L1 mAb as monotherapy is ~20% in urothelial carcinomas [58,59,60], ~15% in non-small-cell lung cancer (NSCLC) [61,62], and ~30% in Merkel cell carcinoma [5,6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.